Liu Ying, Han Mei, Liu Xingdang, Deng Yanping, Li Yu, Yuan Jie, Lv Rongbin, Wang Yuankai, Zhang Guangming, Gao Jinlong
Key Laboratory of Radiopharmaceuticals, College of Chemistry, Beijing Normal University, 19 Xinjiekouwai Street, Haidian district, Beijing, China.
Psychopharmacology (Berl). 2013 Nov;230(2):235-44. doi: 10.1007/s00213-013-3148-z. Epub 2013 May 29.
Previous imaging studies have indicated that the levels of the dopamine transporter (DAT) are reduced in the brains of heroin users. However, whether these changes can be reversed by abstinence and/or treatment remains unclear.
This study aims to investigate DAT availability in heroin users and changes in DAT availability after abstinence and treatment with the Jitai tablets, a traditional Chinese medicinal product that is approved for the treatment of opioid addiction.
Single-photon emission computed tomography (SPECT) with [(99m)Tc] TRODAT-1 was performed on heroin-dependent patients (n = 64) and healthy controls (n = 15). The patients were randomly assigned to treatment with either placebo or the Jitai. All patients underwent SPECT imaging both at baseline and after 6 months of treatment. DAT availability was assessed in the caudate and putamen. Depression and anxiety were evaluated at baseline.
DAT availability remained at low levels during a 6-month period in the placebo-treated group but was increased (14-17 %) in the Jitai-treated group. The ratio of DAT availability at month 6 to that at baseline in the Jitai-treated group was significantly higher than that in the placebo-treated group in both the bilateral caudate and putamen. DAT uptake in the striatum was significantly correlated with daily heroin dose, years of heroin use, and depression.
These findings suggest that chronic heroin use induces long-lasting striatal DAT reductions. DAT availability remained unchanged during a 6-month period of abstinence. Treatment with Jitai appears to be effective at increasing striatal DAT availability.
先前的影像学研究表明，海洛因使用者大脑中的多巴胺转运体（DAT）水平降低。然而，这些变化是否能通过戒断和/或治疗得到逆转仍不清楚。
本研究旨在调查海洛因使用者的DAT可用性，以及在戒断和使用已获批用于治疗阿片类成瘾的中成药济泰片治疗后DAT可用性的变化。
对64例海洛因依赖患者和15例健康对照者进行了用[（99m）Tc]TRODAT-1的单光子发射计算机断层扫描（SPECT）。患者被随机分配接受安慰剂或济泰片治疗。所有患者在基线和治疗6个月后均接受SPECT成像。在尾状核和壳核中评估DAT可用性。在基线时评估抑郁和焦虑情况。
在安慰剂治疗组中，DAT可用性在6个月期间一直保持在低水平，但在济泰片治疗组中有所增加（14%-17%）。在双侧尾状核和壳核中，济泰片治疗组第6个月时的DAT可用性与基线时的比值显著高于安慰剂治疗组。纹状体中的DAT摄取与每日海洛因剂量、使用海洛因的年限及抑郁显著相关。
这些发现表明，长期使用海洛因会导致纹状体DAT持续减少。在6个月的戒断期内，DAT可用性保持不变。济泰片治疗似乎能有效提高纹状体DAT可用性。
